Drug Information

Drug General Information
Drug ID
D09LKM
Former ID
DIB021153
Drug Name
Pyrazolo[1,5-a]pyrimidine 3G
Synonyms
KDR/Flk-1 kinase inhibitor IV; pyrazolo[1,5-a]pyrimidine 3g
Drug Type
Small molecular drug
Indication Discovery agent Investigative [526462]
Formula
C17H13N3OS
InChI
InChI=1S/C17H13N3OS/c1-21-15-4-2-12(3-5-15)14-8-18-17-16(9-19-20(17)10-14)13-6-7-22-11-13/h2-11H,1H3
InChIKey
HBWLNACPIFKNIP-UHFFFAOYSA-N
PubChem Compound ID
5329468
PubChem Substance ID
8035051, 11061599, 14820903, 26759730, 39302082, 48244437, 51227067, 85787218, 99302835, 103305100, 113912701, 121363827, 128038456, 135711581, 136898982, 142399743, 162492120, 163687132, 175607449, 178102676, 179236151, 198950801, 203087591, 223369890, 229059286
Target and Pathway
Target(s) Vascular endothelial growth factor receptor 2 Target Info Inhibitor [526462]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
Endocytosis
PI3K-Akt signaling pathway
VEGF signaling pathway
Focal adhesion
Proteoglycans in cancer
NetPath Pathway IL2 Signaling Pathway
PANTHER Pathway Angiogenesis
VEGF signaling pathway
Pathway Interaction Database HIF-2-alpha transcription factor network
Beta3 integrin cell surface interactions
Signaling events mediated by TCPTP
SHP2 signaling
S1P1 pathway
VEGF and VEGFR signaling network
Integrins in angiogenesis
Signaling events mediated by VEGFR1 and VEGFR2
Notch-mediated HES/HEY network
Reactome Neurophilin interactions with VEGF and VEGFR
VEGF binds to VEGFR leading to receptor dimerization
Integrin cell surface interactions
EPHA-mediated growth cone collapse
VEGFA-VEGFR2 Pathway
VEGFR2 mediated cell proliferation
WikiPathways Focal Adhesion
Nifedipine Activity
Cardiac Progenitor Differentiation
Signaling by VEGF
Angiogenesis
References
Ref 526462Bioorg Med Chem Lett. 2002 Dec 16;12(24):3537-41.Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics.
Ref 526462Bioorg Med Chem Lett. 2002 Dec 16;12(24):3537-41.Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.